An investigation on behalf of investors in Loxo Oncology Inc (NASDAQ:LOXO) shares over potential wrongdoing at Loxo Oncology Inc was announced and NASDAQ:LOXO stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/20/2017 -- An investigation was announced for investors in NASDAQ:LOXO shares concerning potential breaches of fiduciary duties by certain directors at Loxo Oncology.
Investors who purchased shares of Loxo Oncology Inc (NASDAQ:LOXO) and currently hold any of those NASDAQ:LOXO shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Loxo Oncology Inc officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Stamford, CT based Loxo Oncology, Inc. is a United States-based biopharmaceutical company that is engaged in developing selective medicines for patients with genetically defined cancers.
Loxo Oncology Inc went public in August 2014 and shares of Loxo Oncology Inc (NASDAQ:LOXO) reached as high as $44.95 per share.
On February 17, 2017, NASDAQ:LOXO shares closed at $41.74 per share.
Those who purchased shares of Loxo Oncology Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego